Zepbound Beats Wegovy in Clinical Trial

Written by Johnathon Anderson, Ph.D., a research scientist specializing in regenerative medicine and serving as an Associate Professor at the University of California Davis School of Medicine

Zepbound vs Wegovy for Weight Loss

Eli Lilly's anti-obesity medication, Zepbound, has outperformed Novo Nordisk's Wegovy in a head-to-head clinical trial, according to data released by Lilly.

Zepbound Beats Wegovy in Clinical Trial

The study evaluated weight loss outcomes over 72 weeks of treatment, revealing that Zepbound resulted in an average reduction of 20.2% of body weight compared to Wegovy's 13.7%. This indicates that patients taking Zepbound lost 47% more body weight compared to patients taking Wegovy.

These findings indicate that Zepbound has superior weight-loss potential compared to Wegovy. This is the first randomized, head-to-head clinical trial directly comparing Zepbound to Wegovy to manage obesity. The outcome provides Lilly with robust evidence to support its product when engaging with healthcare providers and potential patients.

Zepbound Beats Wegovy in clinical trial, but Novo Nordisk retains a significant advantage with Wegovy because it's the only anti-obesity drug currently demonstrated to reduce the risk of heart attacks and strokes in individuals with pre-existing cardiovascular disease.

Both companies have progressed in addressing previous supply chain issues for their drugs. Both companies are intensifying their promotional efforts as they vie for dominance in the rapidly expanding obesity treatment market.

The question remains whether these distinct benefits—superior weight loss for Zepbound versus cardiovascular protection with Wegovy—will influence prescribing patterns among physicians and preferences among patients.